Melvin Spigelman

Dr. Melvin Spigelman is President and CEO of the Global Alliance for TB Drug Development (TB Alliance) and serves as Co-Chair of the Working Group on New TB Drugs of the Stop TB Partnership. Prior to joining the TB Alliance, he served in leading research and development positions at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Corporation, including as Vice President, Global Clinical Centers. In addition, Dr. Spigelman has served as a board member of multiple publicly listed biotechnology companies, including The Medicines Company (acquired by Novartis). He holds a Doctor of Medicine degree from the Mount Sinai School of Medicine, where he also worked as an Associate Professor.